US EditionPublished • loading... • Updated
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
Summary by Financial Post
2 Articles
2 Articles
WellandTribune.caReposted by 
Financial Post
Financial PostOncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, as well as antisense and small molecule injectable drugs…
Coverage Details
Total News Sources2
Leaning Left1Leaning Right1Center0Last UpdatedBias Distribution50% Left, 50% Right
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
50% Right
L 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
